Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company's lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience, Inc.

Let’s take a look at the upcoming stock splits for the week of August 24 to August 28, based on TipRanks’ Stock Splits Calendar. But before getting...

Upcoming Stock Splits This Week (August 24 to August 28) – Stay Invested

Skye Bioscience ( ($SKYE) ) just unveiled an update. On August 18, 2026, Skye Bioscience received a notice from Nasdaq that its stockholders’ equit...

Skye Bioscience Faces Nasdaq Compliance and Delisting Risk

Skye Bioscience ( ($SKYE) ) has issued an announcement. On August 14, 2026, Skye Bioscience agreed to acquire U.K.-based Redx Pharma, combining to ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SKYE	$1.86	+4.49%	183.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SKYE	$1.86	+4.5%	183.11K
3
4
5
6

SKYE

Get Skye Bioscience, Inc. Data in Excel

Get Skye Bioscience, Inc. Data in Excel